WCI

게시글 내용
Nuclear Science Committee tackles molybdenum supply
wci Hit 9844	2016/11/10
Nuclear Science Committee tackles molybdenum supply In September 2016 the Nuclear Science Advisory Committee, a body providing advice to the US Department of Energy and National Science Foundation, held a meeting on the status of molybdenum-99 supply. The meeting had two central purposes, i.e. to receive updates from domestic molybdenum manufacturers and to present molybdenum supply and demand projections that were produced by the Organization for Economic Co-Operation and Development (OECD). Beginning in 2009, the National Nuclear Security Administration partnered with U.S. companies to accelerate the development of non-enriched domestic sources of molybdenum. Current partners include NorthStar Medical Radioisotopes and SHINE Medical Technologies, who recently relocated to Janesville, Wisconsin to prepare for the construction of their radioisotope production facility. In 2011, the OECD expressed a strong view that molybdenum producers should recover their full cost of production to ensure supply chain security. While they are on their way to achieving full cost recovery, the process is happening at different speeds—and not everywhere. The reserve supply is still insufficient in the case of an unplanned shutdown. To read more please visit http://www.healthimaging.com/topics/technology-management/nuclear-science-committee-tackles-isotope-supply Source: Health Imaging

Nuclear Science Committee tackles molybdenum supply

In September 2016 the Nuclear Science Advisory Committee, a body providing advice to the US Department of Energy and National Science Foundation, held a meeting on the status of molybdenum-99 supply. The meeting had two central purposes, i.e. to receive updates from domestic molybdenum manufacturers and to present molybdenum supply and demand projections that were produced by the Organization for Economic Co-Operation and Development (OECD).

Beginning in 2009, the National Nuclear Security Administration partnered with U.S. companies to accelerate the development of non-enriched domestic sources of molybdenum. Current partners include NorthStar Medical Radioisotopes and SHINE Medical Technologies, who recently relocated to Janesville, Wisconsin to prepare for the construction of their radioisotope production facility.

In 2011, the OECD expressed a strong view that molybdenum producers should recover their full cost of production to ensure supply chain security. While they are on their way to achieving full cost recovery, the process is happening at different speeds—and not everywhere. The reserve supply is still insufficient in the case of an unplanned shutdown.

Source: Health Imaging

WCI

RI Related News

비회원이 작성한 글입니다!